ABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer Therapy

HALIFAX, NS, March 31, 2026 /PRNewswire/ - ABK Biomedical and the University of Missouri Research Reactor (MURR) are powering the next generation of cancer treatment. Today, the two partners signed a ...
Business Insider

ABK Biomedical Raises USD 30M in Series C Financing

Funding supports Eye90 microspheres® FDA IDE approval toward U.S. pivotal study execution and ongoing clinical operations. HALIFAX, NS, Dec. 6, 2022 /PRNewswire/ - ABK Biomedical, Inc., an innovative ...
KOMU 8

MU launches in-person clinical trial with ABK Biomedical for cancer treatment breakthrough

The MU Research Reactor has partnered with ABK Biomedical to conduct an in-person clinical trial targeted at finding a treatment for liver tumors.
Yahoo Finance

ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer

HALIFAX, NS, Feb. 24, 2026 /CNW/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical ...
WREG

ABK Biomedical announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic ...
WDTN

ABK Biomedical Raises US$35M in Series D Financing

HALIFAX, NS, Oct. 14, 2025 /PRNewswire/ - ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical ...
WRIC

ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma

"This is an exciting time for multidisciplinary, liver cancer treatment teams." said Dr. Wang. "Hepatocellular Cancer (HCC) is a severe form of cancer. Over the past 40 years, liver cancer incidence ...
MarketWatch

ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer

The MarketWatch News Department was not involved in the creation of this content. Final Patient Treated in FDA IDE Study Evaluating Eye90 microspheres(R) for the Treatment of Unresectable ...